Triple
T19157788
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Ridgeback Biotherapeutics |
E468969
|
entity |
| Predicate | developedProduct |
P73
|
FINISHED |
| Object | molnupiravir |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: molnupiravir | Statement: [Ridgeback Biotherapeutics, developedProduct, molnupiravir]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: molnupiravir Context triple: [Ridgeback Biotherapeutics, developedProduct, molnupiravir]
-
A.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
-
B.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
C.
Comirnaty
Comirnaty is the brand name of the Pfizer–BioNTech mRNA COVID-19 vaccine used worldwide for the prevention of coronavirus infection.
-
D.
REGN-COV2
REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
-
E.
Epclusa
Epclusa is a prescription antiviral medication used to treat chronic hepatitis C infection across all major genotypes.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: molnupiravir Target entity description: Molnupiravir is an oral antiviral medication used to treat COVID-19 by inhibiting replication of the SARS-CoV-2 virus.
-
A.
velpatasvir
Velpatasvir is a direct-acting antiviral medication used in combination with sofosbuvir to treat chronic hepatitis C virus infection across multiple genotypes.
-
B.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
C.
Comirnaty
Comirnaty is the brand name of the Pfizer–BioNTech mRNA COVID-19 vaccine used worldwide for the prevention of coronavirus infection.
-
D.
REGN-COV2
REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
-
E.
Epclusa
Epclusa is a prescription antiviral medication used to treat chronic hepatitis C infection across all major genotypes.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8dd084ff48190ac0f8c46ee722629 |
completed | April 10, 2026, 11:20 a.m. |
| NER | Named-entity recognition | batch_69e5eeba91a081909c04d61d6117da06 |
completed | April 20, 2026, 9:15 a.m. |
Created at: April 10, 2026, 12:06 p.m.